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Abstract
An estimated 34 million people are living with HIV worldwide (UNAIDS, 2012), with the number of infected persons rising
every year. Increases in HIV prevalence have resulted not only from new infections, but also from increases in the survival of
HIV-infected persons produced by effective anti-retroviral therapies. Augmentation of anti-viral immune responses may be
able to further increase the survival of HIV-infected persons. One strategy to augment these responses is to reinvigorate
exhausted anti-HIV immune cells present in chronically infected persons. The PD-1-PD-L1 pathway has been implicated in
the exhaustion of virus-specific T cells during chronic HIV infection. Inhibition of PD-1 signaling using blocking anti-PD-1
antibodies has been shown to reduce simian immunodeficiency virus (SIV) loads in monkeys. We now show that PD-1
blockade can improve control of HIV replication in vivo in an animal model. BLT (Bone marrow-Liver-Thymus) humanized
mice chronically infected with HIV-1 were treated with an anti-PD-1 antibody over a 10-day period. The PD-1 blockade
resulted in a very significant 45-fold reduction in HIV viral loads in humanized mice with high CD8+ T cell expression of PD-1,
compared to controls at 4 weeks post-treatment. The anti-PD-1 antibody treatment also resulted in a significant increase in
CD8+ T cells. PD-1 blockade did not affect T cell expression of other inhibitory receptors co-expressed with PD-1, including
CD244, CD160 and LAG-3, and did not appear to affect virus-specific humoral immune responses. These data demonstrate
that inhibiting PD-1 signaling can reduce HIV viral loads in vivo in the humanized BLT mouse model, suggesting that
blockade of the PD-1-PD-L1 pathway may have therapeutic potential in the treatment of patients already infected with the
AIDS virus.
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Introduction
Antiviral T cells play a pivotal role in the control of viremia
during acute and chronic Human Immunodeficiency Virus (HIV)
infection. Compelling data show that CD8+ T cell responses are a
major component of human immune response associated with the
precipitous decline from peak viremia during acute HIV infection
[1,2,3]. These CD8+ T cells can inhibit HIV replication in vitro [4],
and experimental depletion of CD8+ T cells in non-human
primates infected with SIV abrogated their inability to contain
peak viremia in acute infection, and increased viremia during
chronic infection [5]. In addition to cytotoxicity to infected cells
[6], effective CD8+ T cells may control HIV replication through a
number of other mechanisms, including the release of soluble
factors such as CCR5 chemokine ligands capable of inhibiting
HIV replication [4,7,8,9,10,11].
Despite the apparent ability of immune responses to restrain
HIV viremia to a relatively stable plateau during the prolonged
phase of chronic infection, progression to AIDS ultimately ensues
in most HIV-infected persons, accompanied by dramatic increases
in levels of viremia. In contrast to the high functional capacity of
effector and memory CD8+ T cells generated after acute viral
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infection, CD8+ T cell function is often impaired or exhausted
during chronic infections [12]. T cell exhaustion was originally
described during chronic lymphocytic choriomeningitis virus
(LCMV) infection in mice in which virus-specific CD8+ T cells
persisted indefinitely but had reduced capacity to kill infected cells
or secrete antiviral cytokines [12]. Primate and human studies
have demonstrated the presence of dysfunctional CD8+ T cells
during chronic infections with SIV in primates, as well as chronic
HIV, hepatitis B, hepatitis C, and human T lymphotropic virus
(HTLV) infections in humans [13].
Programmed Death 1 (PD-1, CD279) is highly expressed on
exhausted CD8+ T cells in chronic LCMV infected mice [14].
Inhibiting PD-1 signaling in vivo using mAbs to either PD-1 itself or
its ligand PD-L1 during chronic LCMV infection dramatically
enhanced virus-specific T cell number and function leading to a
marked reduction in viral load [14]. The PD-1-PD-L1 pathway
was subsequently found to play a major role in CD8+ T cell
dysfunction in chronic HIV infection in humans [15,16,17]. PD-1
is highly expressed on exhausted HIV-specific CD8+ T cells, and
its levels correlate with measures of disease severity, such as viral
load and declining CD4 count. Blockade of the pathway ex vivo
with mAbs to PD-1 or PD-L1 leads to increased HIV-specific
CD8+ T cell proliferation and production of IFNc, TNFa, and
granzyme B, indicating an overall increase in effector function
[15,16,17]. Recently, in vivo blockade of the PD-1-PD-L1 pathway
using anti-PD-1 mAb in chronic SIV-infected macaques resulted
in rapid expansion of virus-specific CD8+ T cells with improved
effector function [18]. Most importantly, the blockade was
associated with significant reduction in viral load and prolonged
survival of the SIV-infected macaques.
The limited species tropism of the HIV virus has made it very
difficult to study in animal models. In efforts to ‘‘humanize’’ mice
to render them permissive for HIV infection, investigators began
to engraft human immune cells and/or tissues into immunodefi-
cient mice that are unable to reject xenogeneic grafts [19]. Early
versions of humanized mice used for HIV investigation were
generated by transfer of mature human peripheral blood
lymphocytes into mice homozygous for the severe combine
immune deficiency (scid) mutation (Hu-PBL-scid mice) [20], or
transplantation of fetal human thymus and liver tissues into scid
mice (SCID-Hu mice) [21]. These mice are able to support
productive HIV infection in vivo [22,23] and have provided
investigators with useful models of HIV infection for some
applications, but have important limitations. These mice generally
lack robust primary adaptive immune responses, thus limiting their
usefulness for studying anti-HIV immune responses and mecha-
nisms by which the virus evades these responses [24]. However,
recent improvements in humanized mouse models of HIV
infection have generated mice that are able to generate robust
cellular HIV-specific responses in vivo. One of the most successful
of the recently developed models is the BLT (Bone Marrow-Liver-
Thymus) humanized mouse, which is generated by surgically
implanting human fetal thymic and liver tissue into immunode-
ficient mice concurrently with the transfer of human hematopoi-
etic stem cells [25,26,27]. Importantly in this model, human T
cells are educated by autologous human thymic tissue. BLT mice
demonstrate robust repopulation of mouse mucosal tissues with
human immune cells that support rectal and vaginal transmission
of HIV [28,29], and robust repopulation of mouse lymphoid
tissues with functional human T lymphocytes [26,27,30] able to
force the evolution of HIV ‘‘escape mutations’’ [31].
We previously reported human T cells in chronically HIV-
infected BLT mice demonstrate increased PD-1 expression, and
that T cell PD-1 levels in these mice correlate positively with viral
loads and inversely with CD4+ cell levels, as seen in human
infection [25]. Here we demonstrate that substantial CD8+ T cell
upregulation of PD-1 occurs in most, but not all, chronically HIV-
infected BLT mice, and that PD-1 mAb treatment significantly
reduces viral load specifically in those mice with high CD8+PD-1+
cells. Without PD-1 blockade, control mice maintained peak viral
loads for months after HIV infection, despite our previous
demonstration that acute CD8+ T cell responses in these mice
are similar to humans in terms of specificity, kinetics, and
dominant targets [31].
Materials and Methods
BLT humanized mice
NOD/SCID/IL2Rcc
2/2 (NSG) mice (The Jackson Laborato-
ry) were housed in a pathogen-free facility at Massachusetts
General Hospital, maintained in microisolator cages, fed auto-
claved food and water, and reconstituted with human tissue as
previously described [25]. Briefly, sublethally irradiated NSG mice
received 1 mm3 fragments of human fetal liver and thymus that
were implanted under one kidney capsule, and 56104–16105
purified autologous CD34+ hematopoietic stem cells isolated from
the fetal liver were injected intravenously. After 14–18 weeks,
healthy mice that met the following criteria for adequate human
reconstitution were used in experiments: (1) .25% of peripheral
blood cells were within a lymphocyte gate on forward-versus-side
scatter plots; (2).50% of cells in the lymphocyte gate were human
(hCD45+/mCD452); and (3) .40% of human cells in the
lymphocyte gate were T cells (hCD3+). Two different human
fetal donors were used to generate the BLT mice used in this
study.
Ethics Statement
This study was carried out in strict accordance with the
recommendations contained in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
protocols were approved by the Subcommittee on Research and
Animal Care (SRAC), which serves as the Institutional Animal
Care and Use Committee (IACUC) for Massachusetts General
Hospital (Protocol # 2009N000136).
HIV infections
Viral stocks of the R5-tropic HIV-1 molecular clone JR-CSF
were produced through transfection of human embryonic kidney
(HEK) 293T cells, and titered as described [32]. Mice were
infected intraperitoneally with 56104 TCID50 of JR-CSF HIV-1.
Every 2–4 weeks after infection, approximately 200 ml of blood
was obtained through puncture of the retro-orbital sinus for
isolation of plasma virus.
RNA isolation and viral load measurement
Viral RNA was isolated from plasma samples with the QIAamp
Viral RNA Mini Kit (Qiagen). Plasma viral loads were determined
by quantitative RT-PCR with the QuantiFast SYBR Green RT-
PCR kit (Qiagen) as described [32].
In vivo antibody treatment
BLT mice were injected with either a partially humanized
mouse anti-human PD-1 mAb (clone EH12-1540-29C9) or a
control mAb (SYNAGIS). This anti-PD-1 mAb has mouse
variable heavy chain domain linked to human IgG1 (mutated to
reduce FcR and complement binding) and mouse variable light
chain domain linked to human Kappa. This anti-PD-1 mAb has
been shown to bind to human PD-1 and block interactions
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between PD-1 and its ligands [18,33]. SYNAGIS is a humanized
mouse monoclonal antibody (IgG1k) specific to F protein of
respiratory syncytial virus (RSV) (Medimmune, Gaithersberg,
MD). Antibodies (200 mg/dose) were administered intraperitone-
ally at on days 0, 3, 7 and 10. The dosage and schedule were based
on prior in vivo administration of these antibodies in macaques
infected with SIV [18].
Flow Cytometry
PBMCs obtained from BLT mice were stained and analyzed
using an LSRII flow cytometer (BD Biosciences). Fluorescently
labeled anti-human CD45, CD4, CD8, CD244, CD160, and PD-
1 Abs were obtained from BioLegend (San Diego, CA).
Fluorescently labeled anti-human LAG-3 Ab was obtained from
R&D Systems.
Western Blotting
HIV-specific IgM and IgG human antibodies were detected in
plasma samples from HIV-infected BLT mice using Genetic
Systems (GS) HIV-1 Western Blot kits (Bio-Rad) according to the
manufacturer’s instructions, substituting mouse anti-human IgM
and anti-human IgG antibodies conjugated to horseradish
peroxidase (Southern Biotech, AL) for the anti-human Ig antibody
supplied. Antibodies were detected in a final dilution of mouse
plasma of 1:101, the same dilution as that recommended by the
manufacturer for the detection of HIV-specific antibodies in
human clinical samples. The Western Blots were developed with
ECL Plus Western blotting detection reagents (GE Healthcare).
ELISAs
ELISAs to determine titers of IgG antibodies binding to p24
and gp120 were performed as follows. Microtiter plates (Nunc
MaxiSorp, Thermo Scientific) were coated with 0.25 mg/ml
recombinant p24 (HXBc2) or gp120 (JRCSF) (Immune Technol-
ogy Corp, NY) overnight at 4uC. Plates were blocked with 5%
bovine serum albumin (BSA) before being incubated with serial
dilutions of plasma samples or HIVIG control (NIH AIDS
Reagent Program) in phosphate-buffered saline (PBS), for
1.5 hours at room temperature. Antibody binding was detected
with HRP-labeled anti-human IgG monoclonal antibody (1:1,000;
Southern Biotech) and a TMB peroxidase substrate (KPL, MD).
Statistical analysis
Mann-Whitney tests or Wilcoxon matched pairs tests were
determined using Prism software (GraphPad Software, Inc.) to
assess statistical significance. All tests were two tailed, and P,0.05
was considered significant.
Results
PD-1 expression on CD8+ T cells increased in chronic HIV-
1 infection
Humanized BLT mice were created as previously described
[25] with all experimental mice having met the criteria for
adequate human reconstitution outlined in the Materials and
Methods section. BLT mice were infected with HIV-1 virus on
Week 0, as depicted in Figure 1. Peripheral blood samples were
obtained serially every few weeks after infection for analyses.
Infected BLT mice showed a significant increase in the percentage
of CD8+ cells expressing PD-1 at 13 weeks post infection (p.i.)
when compared to an earlier time point at 7 weeks p.i. or to
uninfected BLT mice (Figure 2A). At 13 weeks p.i., 38.7614.7%
of CD8+ T cells expressed PD-1 on their surface, which is 1.6-fold
more than at 7 weeks p.i. (24.1621.6%) and 3.2-fold more than in
uninfected controls (11.9610.2%). In contrast, PD-1 expression
on CD4+ T cells did not significantly increase in HIV-infected
BLT mice at 13 weeks p.i. compared to earlier time points p.i. or
to uninfected mice.
PD-1 expression on CD8+ T cells varied among
chronically HIV-infected BLT mice
Although the majority of the HIV-infected BLT mice demon-
strated a dramatic increase in PD-1 expression on their CD8+ T
cells, some mice did not. Different extents of CD8+ T cell PD-1
expression observed at 13 weeks p.i. are shown for two HIV-
infected mice in Figure 2B: 63.9% of the CD8+ T cells of the
mouse designated ‘‘PD1-HI’’ were PD-1+ (as were 18.2% of the
CD4+ T cells of this mouse), whereas 19.4% of the CD8+ T cells
(and 7.2% of the CD4+ T cells) of the ‘‘PD1-LO’’ mouse expressed
PD-1. These differences in PD-1 expression occurred despite these
two mice having similar HIV viral loads at this time point: the
PD1-HI mouse had 2.056106 copies of HIV/mL, whereas the
PD1-LO mouse had 2.426106 copies/mL. In the 18 HIV-
infected mice evaluated at 13 weeks p.i., PD-1 expression ranged
from a high of 63.9% to a low of 5.8% on CD8+ T cells, and from
37.9% to 2.3% on CD4+ T cells (Figure 2A). These varying
percentages did not correlate with HIV viral loads, indicating
variability in human immune responses among individual BLT
mice with comparable HIV infections. As described in the
following section, HIV-infected BLT mice were treated with
either anti-PD-1 mAb at 13 weeks p.i., with control mAb, or
received no further treatment. We hypothesized that PD-1
blockade would produce different effects in HIV-infected BLT
mice with high versus low levels of CD8+ cells expressing PD-1.
We therefore divided mice treated with anti-PD-1 mAb into 2
groups based on their PD-1+CD8+ levels: 1) a ‘‘PD1-LO’’ group
with 3 mice with less than 30% PD-1+CD8+ cells, and 2) a ‘‘PD1-
HI’’ group with 5 mice with more than 30% PD-1+CD8+ cells
Figure 1. Schematic of BLT humanized mouse generation and timeline of HIV-1 infection and anti-PD-1 mAb treatment.
doi:10.1371/journal.pone.0077780.g001
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(Figure 2C). The percentage of CD4+ cells expressing PD-1 was
not a factor in grouping the mice.
In vivo anti-PD-1 mAb treatment decreased HIV viral load
PD-1 signaling was inhibited with a humanized mouse antibody
specific to human PD-1 that blocks the interaction between PD-1
and its ligands (PD-L1 and PD-L2). Like the mAbs used in clinical
trials of tumor immunotherapy [34], this antibody has an Fc that
does not engage FcR or deplete PD-1+ cells. In order to determine
if PD-1 blockade could lower HIV viral loads during the chronic
phase of infection, BLT mice infected with HIV for at least 13
weeks (the time point where most CD8+ cells showed upregulation
Figure 2. PD-1 expression on T cells in HIV-infected BLT mice. Peripheral blood was obtained at various time points after HIV infection.
A) Percentages of human CD8+ and CD4+ T cells expressing PD-1. Horizontal lines within data points depict mean value. Uninfected controls were
from peripheral blood samples obtained at time points when littermates were infected for 9-13 weeks. (HIV infected: n = 9 mice at wk 3, n = 18 mice
at other time points; Uninfected: n = 7 mice). *P= 0.01, Wilcoxon matched pairs test; **P= 0.001, Mann-Whitney test. B) Representative flow cytometry
data of PD1 expression on CD8+ or CD4+ T cells at 13 weeks post infection. PD1-HI representative is mouse #4 and PD1-LO is mouse #1 depicted in
the next panel. C) Percentages of CD8+ and CD4+ T cells expressing PD-1 in PD1-LO (defined as having ,30% PD-1+CD8+ cells) and PD1-HI (.30%
PD-1+CD8+ cells).
doi:10.1371/journal.pone.0077780.g002
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of PD-1) were treated with anti-PD-1 mAb. At 13 weeks p.i., the
mean viral load of the 18 infected BLT mice was 1.36106 copies/
mL (SEM=3.16105). BLT mice in the Control group were either
treated with isotype-matched control antibody (SYNAGIS) (n = 5)
or did not receive any antibody treatment (n = 5). There were no
significant differences in any parameter evaluated between mice
receiving control mAb and mice receiving no Ab treatment.
Therefore, mice receiving control or no Ab were analyzed
together as a single control group. PD-1 blockade of the ‘‘PD1-
LO’’ mice showed no significant change in their HIV viral loads
from that of the Control mice (Figure 3). In contrast, PD-1
blockade of the ‘‘PD1-HI’’ mice dramatically decreased their HIV
viral loads 5 weeks following the first dose of anti-PD-1 mAb by
1.7 logs (45-fold) compared to Controls, 1.4 logs (24-fold)
compared to the ‘‘PD1-LO’’ group, and 1.4 logs (22-fold)
compared to their pretreatment levels. The reduced viral loads
in the ‘‘PD1-HI’’ group persisted for at least 9 weeks after the first
treatment with anti-PD-1 mAb, after which the mean viral load
started to increase at 13 weeks post treatment (Figure 3). This rise
in viral loads 13 weeks following anti-PD-1 mAb treatment may
reflect re-emergence of T cell exhaustion, emergence of viral
escape mutations, or both. Declines in HIV viral loads were noted
in the Control group at 22 and 26 weeks p.i., possibly due to
declines in CD4+ T cell numbers, as shown in Figure 4a from 16-
18 weeks to 26-30 weeks p.i. (P=0.047), and previously noted by
us at these times in other HIV-infected BLT mice [25].
Anti-PD-1 mAb treatment affected T cells, but not B cell
responses
Concurrent with viral load reductions, PD-1 blockade produced
significant increases in the percentages of CD8+ T cells in the
peripheral blood of chronically HIV-infected BLT mice which had
high levels of CD8+PD-1+ expression. At 3 to 5 weeks following
the initiation of anti-PD-1 mAb treatment, the percentage of
CD8+ T cells in ‘‘PD1-HI’’ mice was 2.6-fold greater than in
Control mice that were treated with control or no antibody
(P=0.0007), and 2.7-fold greater in the ‘‘PD1-HI’’ mice prior to
anti-PD-1 treatment (Figure 4a). In contrast, PD-1 blockade
produced no significant changes in the percentage of CD4+ T cells
in the ‘‘PD1-HI’’ mice compared with Control HIV-infected mice
(Figure 4a) or with ‘‘PD1-HI’’ mice prior to anti-PD-1 treatment.
By 13–17 weeks following the initiation of anti-PD-1 antibody
treatment, the increase in the percentage of CD8+ T cells in ‘‘PD1-
HI’’ mice was no longer statistically significant compared with
control HIV-infected mice (Figure 4a). The percentages of CD8+
or CD4+ T cells in ‘‘PD1-LO’’ mice were not significantly different
from control HIV-infected mice or from the pre-mAb treatment
levels in ‘‘PD1-LO’’ mice at either of the post-mAb treated time
points evaluated (Figure 4a). The results suggest that PD-1
blockade produced a significant expansion of human CD8+ T
cells, but not CD4+ T cells, in chronically HIV-infected BLT mice
that had high levels of PD-1 expression on their CD8+ T cells.
PD-1 blockade did not affect the breadth or magnitude of anti-
HIV antibody responses in chronically infected BLT mice.
Western blots demonstrated both human IgM and IgG antibodies
to multiple HIV antigens, including gp160, gp120, p65, p40, and
p24, were generated in chronically infected mice (indicating that
antibody class switching occurs in these animals, Figure 4b).
However, anti-PD-1 mAb treatment of ‘‘PD1-HI’’ mouse did not
increase the number of HIV antigens targeted compared to that
treated with control Ab (Figure 4b). Anti-HIV Ab ELISAs
demonstrated that anti-PD-1 mAb also did not increase antibody
titers to those antigens that were targeted: IgG Ab titers to HIV
p24 were found to be similar between anti-PD-1 mAb and control
Ab-treated groups (Figure 4c), as were IgG titers to HIV envelope
gp120 (Figure 4d).
Co-expression of PD-1 with other inhibitory receptors
differed between CD8+ and CD4+ T cells in chronically
HIV-infected BLT mice
In addition to PD-1, exhausted T cells may express a number of
other inhibitory receptors during chronic infection, and co-
expression of multiple inhibitory receptors has been associated
with greater T cell exhaustion and more severe infection [35]. We
consequently analyzed the co-expression of PD-1 with other
inhibitory receptors associated with exhaustion, CD244, CD160,
and LAG-3, by CD4+ and CD8+ cells in chronically HIV-infected
BLT mice (Figure 5a). There were no significant differences in the
percentages of PD-1-expressing CD8+ or CD4+ T cells that co-
expressed CD244 or CD160 cells between the ‘‘PD1-HI’’ and
Figure 3. Effects of anti-PD-1 mAb or control treatment on HIV viral loads in chronically infected BLT mice. BLT mice infected with HIV-
1 for 13 weeks were injected intraperitoneally with anti-PD-1 mAb, control mAb, or no Ab on days 0, 3, 7 and 10 (200 mg/dose, arrow). Peripheral
blood was collected at multiple time points and HIV-1 plasma viral load was measured by quantitative RT-PCR. Graph represents mean viral load of
Control (n = 10, control mAb or no Ab), anti-PD-1 mAb-treated PD1-LO mice (n = 3), and anti-PD-1 mAb-treated PD1-HI mice (n = 5). *P,0.05, Mann-
Whitney test.
doi:10.1371/journal.pone.0077780.g003
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Figure 4. Cellular and humoral responses after anti-PD-1 mAb treatment. A) Percentages of human CD8+ and CD4+ T cells from lymphocyte
gate at 13, 16–18 and 26–30 weeks post infection (p.i.), times corresponding to 0, 3–5 and 13–17 weeks after start of anti-PD-1 mAb treatment (a.t.),
respectively. Horizontal lines within data points depict mean values. *P=0.0007, Mann-Whitney test; **P= 0.047, Wilcoxon paired test. B) Western
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Control mice before or after treatment with anti-PD-1, or control
Ab, at 13 or 26 weeks p.i.(Figure 5b). Co-expression of LAG-3 by
PD-1 expressing CD8+ T cells was significantly decreased
following anti-PD-1 mAb treatment of ‘‘PD-HI’’ mice compared
to Control mice at 26 weeks p.i. (P=0.035).
There were marked differences in co-expression of PD-1 and
these other inhibitor receptors between CD8+ and CD4+ T cells in
both groups of mice, at both time points, however. An average of
84% of PD-1-expressing CD8+ T cells in mice in the ‘‘PD1-HI’’
and Control groups considered together co-expressed CD244 at
13 weeks p.i., whereas only 12.5% of the PD-1-expressing CD4+
cells of these mice did (P=0.004, Figure 5b). This difference
between CD8+ and CD4+ T cells in PD-1–CD244 co-expression
persisted to 26 weeks p.i. (P=0.008). PD-1–CD160 co-expression
was also greater on the CD8+ than the CD4+ T cells of mice in the
‘‘PD1-HI’’ and control groups considered together, but only at the
later time point of 26 weeks post infection. Few PD-1-expressing
CD8+ or CD4+ T cells co-expressed CD160 at 13 weeks p.i.,
whereas at 26 weeks p.i. 40.1% of PD-1-expressing CD8+ T cells
co-expressed CD160 compared with only 5.4% of PD-1-express-
ing CD4+ T cells (P=0.008, Figure 5b). In contrast, there were no
significant differences in PD-1–LAG-3 co-expression between
CD8+ and CD4+ T cells in the chronically HIV-infected BLT
mice at either time point (Figure 5b).
Discussion
In this study, blockade of the PD-1-PD-L1 pathway using a
short 10 day treatment with anti-PD-1 mAb expanded CD8+ T
cells, and reduced viral loads in chronically HIV-infected BLT
humanized mice by almost 2 logs, compared to control mice.
These results extend our previous report that CD8+ T cell
responses in acutely HIV-infected BLT mice resemble those in
humans in terms of their specificity, kinetics, and immunodomi-
nance [31]. In acutely-infected BLT mice, we had previously
demonstrated that the generation of HIV-specific CD8+ T cells
was associated with selection of viral escape mutations in well-
defined CD8 epitopes restricted by the human donor HLA alleles
[31]. In this prior study, expression of the protective class I HLA
allele B*57 by the human donor used to reconstitute BLT mice
was associated with more sustained suppression of plasma viremia
[31]. Taken together, these data suggest that the HIV-specific
CD8+ T cells that expand in acutely infected BLT mice are
functionally capable of limiting HIV replication. Our current
study suggests that during more chronic HIV infection of BLT
mice, CD8+ T cells become impaired, or ‘‘exhausted’’, and that
PD-1 blockade can reinvigorate these exhausted T cells to regain
the capacity to limit HIV replication. This in vivo data is consistent
with recent in vitro observations that mAbs to PD-1 and PD-L1 can
augment HIV-specific CD8+ and CD4+ T cell proliferation and
effector functions [15,16,17,36].
Our study also validates recent in vivo demonstrations that
inhibition of PD-1–PD-L1 signaling can reduce levels of SIV or
HIV viremia in macaque [18], and humanized mouse [37],
models of HIV respectively. Adding our results to those of Palmer
and colleagues [37], inhibition of the PD-1–PD-L1 pathway now
has been shown to reduce HIV viral loads in two different
humanized mouse models, with targeting of PD-1 or its ligand PD-
L1. Our study used BLT humanized mice, generated by surgically
implanting fetal human thymic and liver tissues under the renal
capsule of adult mice followed by adoptive transfer of autologous
human fetal-derived CD34+ hematopoietic stem cells [25,26,27],
whereas the study of Palmer et al. [37] used humanized BALB/c-
Rag2–/–cc–/– mice generated by the intrahepatic injection of
human fetal liver-derived CD34+ hematopoietic stem cells into
newborn mice [38]. In contrast to our use of anti-PD-1 mAb to
inhibit PD-1–PD-L1 signaling, Palmer and colleagues used anti-
PD-L1 mAb [37]. It will be of future interest to determine if there
are different mechanisms involved between the two antibodies due
to different target selection and antibody characteristics since PD-1
expression is more restricted than that of PD-L1. In addition, PD-
L1 blockade would leave the PD-L2-PD-1 inhibitory pathway
active whereas PD-1 blockade would leave the PD-L1-CD80
inhibitory pathway active. The ability of PD-1 or PD-L1 blockade
to improve control of viremia in both of these humanized mouse
models of chronic HIV infection underscores the therapeutic
potential that PD-1–PD-L1 inhibition may have in human HIV
infection, similar to its therapeutic potential in human cancer that
has been demonstrated in recent clinical trials [34,39,40,41].
CD8+ T cell expression of PD-1 did not increase uniformly in
the chronically HIV-infected BLT mice in this study: most, but not
all, or these mice demonstrated a dramatic increase in PD-1
expression on their CD8+ T cells. Prior to anti-PD-1 mAb
treatment, HIV viral loads did not differ significantly between
‘‘PD1-HI’’ and ‘‘PD1-LO’’ groups of mice, suggesting that the
differences in PD-1 expression between these mice did not result
from differences in viral antigen burden. Rather, based on their
differing responses to anti-PD-1 mAb treatment, we hypothesize
that these mice differed in the quantities of HIV-specific CD8+ T
cells that they generated prior to Ab treatment, with PD1-HI mice
having a greater number of HIV-specific cells than PD1-LO mice.
This hypothesis would be consistent with data from chronically
HIV-infected humans, in whom significantly higher PD-1 levels
are seen on total CD8+ T cells compared to HIV-seronegative
patients, with the highest PD-1 expression found on tetramer+
HIV-specific CD8+ T cells [15]. This hypothesis would also be
consistent with our observation of reduced HIV viral loads
following anti-PD-1 treatment only in ‘‘PD1-HI’’ mice. Those
mice generating higher amounts of HIV-specific CD8+ T cells
would be expected first to have greater numbers of PD-1+ cells as
those cells become functionally exhausted due to chronic exposure
to viral antigens, and then to have more effective CD8+ T cell
control of viremia as their greater numbers of HIV-specific but
exhausted cells are reinvigorated by PD-1 blockade. This
hypothesis would further be consistent with our observation of
CD8+ T cell expansion following anti-PD-1 treatment only in
‘‘PD1-HI’’ mice. Those mice generating higher amounts of HIV-
specific CD8+ T cells would also be expected to have greater
numbers of cells that would proliferate in response to the high HIV
antigen burden present at the time anti-PD-1 mAb treatment. To
support this hypothesis, we tried to compare the numbers of HIV-
specific CD8+ T cells that were present in the peripheral blood of
‘‘PD1-HI’’ versus ‘‘PD1-LO’’ mice at the time of anti-PD-1 mAb
treatment. Our ability to detect these cells by standard interferon-c
ELISpot assays was precluded, however, by the failure of PBMCs
blot of plasma samples taken from 2 mice before and after anti-PD-1 mAb treatment showing anti-HIV IgG Abs and anti-HIV IgM Abs. *’s depict
positive bands indicating the presence of antibodies to HIV proteins listed at left. Negative Controls, from the same blots as the data, were ‘‘cut-and-
pasted’’ for image layout purposes. HIV-specific binding assays were performed using ELISA to measure IgG titers against C) p24 and D) gp120.
Human plasma samples were collected 6-25 weeks post diagnosis of HIV-1 infection. BLT plasma samples were collected 26 weeks post infection.
doi:10.1371/journal.pone.0077780.g004
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from these mice, after being frozen and thawed, to generate
interferon-c.
HIV infection is associated with B cell dysfunction as well as T
cell dysfunction [42], which has been attributed largely to
bystander effects on B cells of immune activation driven by
ongoing HIV replication [43]. PD-1 blockade in the SIV/
macaque model significantly increased the titer of SIV-specific
antibodies [18], suggesting the possibility that PD-1–PD-L1
signaling contributes to B cell dysfunction in HIV infection. PD-
1 is upregulated on activated B cells [18,44], and consequently
could deliver negative signals to B cells as well as T cells.
Alternatively, PD-1-induced B cell dysfunction could occur
secondary to PD-1-induced dysfunction of T cell help. We
consequently investigated whether PD-1 blockade could also
increase the titer of HIV-specific antibodies in chronically HIV-
infected BLT mice. Several prior studies of HIV infection in other
humanized mouse models found little or no production of HIV-
specific IgM or IgG antibodies post-infection [45,46,47]. In earlier
work with the BLT mouse model, we showed that these mice can
generate antibodies against a number of HIV antigens after
infection, but did not analyze the isotypes of the antibodies
produced [25]. Now we demonstrate that BLT mice can generate
class-switched IgG antibodies against multiple HIV proteins, with
titers approaching those of infected humans. In contrast to the
SIV/macaque study cited above, however, we found PD-1
blockade produced no significant increases in the number of
HIV antigens targeted, or in the titers of p24- or gp120-specific
IgG antibodies, in chronically HIV-infected BLT mice. These
results are consistent with a recent human study showing that titers
and neutralizing activity of HIV-specific antibodies did not
correlate with levels of PD-1expression on B cells in chronically
infected subjects [44], suggesting that the immunological signifi-
cance of PD-1 expression on B cells may be more important in
SIV than HIV infection [43].
Given that exhausted T cells may express a number of other
inhibitory receptors in addition to PD-1 during chronic infection,
and that co-expression of multiple inhibitory receptors has been
associated with greater T cell exhaustion [35], we assessed the co-
expression of three of these other inhibitory receptors, CD244,
CD160, and LAG-3, with PD-1 in chronically HIV-infected mice.
In chronically HIV-infected humans, virus-specific CD8+ T cells
have recently been noted to have substantial co-expression of
CD244 and CD160 with PD-1, but little of LAG-3 [36].
Consistent with these results, we found that in the chronically
HIV-infected BLT mice, the majority of CD8+ T cells co-
expressed PD-1 and CD244, and a substantial minority co-
expressed PD-1 and CD160, whereas few cells co-expressed PD-1
and LAG-3. In contrast to the CD8+ T cells, none of these other
three inhibitory receptors were substantially co-expressed by PD-1
expressing CD4+ T cells in the chronically infected BLT mice. As
blocking both PD-1 and LAG-3 in chronic LCMV infection in
mice has been shown to have additive therapeutic benefits [35], it
will be of interest to determine if blocking CD244 or CD160 could
further improve the control of HIV seen in chronically HIV-
infected humanized mice with inhibition of their PD-1–PD-L
signaling.
The results from this study demonstrate that in vivo blockade of
PD-1 during chronic HIV infection can produce significant
expansions of CD8+ T cells and decreases in viral loads. These
positive effects of antibodies blocking the PD-1-PD-L1 pathway in
humanized mice further indicate that reinvigoration of exhausted
T cells has the potential to be a novel therapeutic approach to
chronic HIV infection, as suggested by studies performed with
human T cells ex vivo and with SIV in macaques in vivo. Our results,
together with those of Palmer and colleagues [37], also suggest that
the new generation of humanized mouse models, with their
improved capacity to model the human immune system, now
appear capable of evaluating novel immunomodulatory approach-
es to HIV infection in humans.
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